IMPACT OF MESALAZINE ON THE RESPONSE TO COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTRE STUDY OF GETECCU (VACOVEII STUDY)
Gastroenterol Hepatol. 2024 Jan 12:S0210-5705(24)00017-7.
doi: 10.1016/j.gastrohep.2023.12.012.
Online ahead of print.
[Article in
English,
Spanish]
Authors
Diego Casas Deza
1
, Ana Belén Julián Gomara
2
, Eva Caudevilla Biota
3
, Belén Beltrán
4
, Eugeni Domènech
5
, Ana Gutiérrez Casbas
6
, Miriam Mañosa
5
, Yamile Zabana
7
, Lourdes Roc Alfaro
8
, Emilio Valverde Romero
8
, Elena García González
9
, Beatriz Sicilia
10
, Viviana Laredo
11
, María José Alcalá Escriche
12
, Lucia Madero Velázquez
13
, Rocío Ferreiro Iglesias
14
, Antonia Palmero Pérez
15
, Margalida Calafat
5
, Saioa Rubio Iturria
16
, Irene Moraleja Yudego
17
, Yolanda Ber Nieto
18
, Sandra García Mateo
11
, Javier P Gisbert
19
, Raquel Vicente Lidón
20
, Lara Arias
10
, Erika Alfambra
21
, Pilar Corsino Roche
1
, Manuel Barreiro de Acosta
14
, Santiago García López
1
Affiliations
- 1 Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet de Zaragoza, Spain; Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Spain.
- 2 Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet de Zaragoza, Spain. Electronic address: belen_zaj@hotmail.com.
- 3 Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Spain.
- 4 Servicio de Aparato Digestivo, Hospital Universitari i Politècnic La Fe de Valencia, Spain.
- 5 Servicio de Aparato Digestivo, Hospital Universitari Germans Trias i Pujol de Badalona, Universitat Autónoma de Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain.
- 6 Servicio de Aparato Digestivo, Hospital General Universitario Doctor Balmis de Alicante, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain; Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Spain.
- 7 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain; Servicio de Aparato Digestivo, Hospital Universitari Mútua Terrassa, Spain.
- 8 Servicio de Microbiología, Hospital Universitario Miguel Servet de Zaragoza, Spain.
- 9 Servicio de Bioquímica, Hospital Universitario Miguel Servet de Zaragoza, Spain.
- 10 Servicio de Aparato Digestivo, Hospital Universitario de Burgos, Spain.
- 11 Servicio de Aparato Digestivo, Hospital Clínico Lozano Blesa de Zaragoza, Spain.
- 12 Servicio de Aparato Digestivo, Hospital Obispo Polanco de Teruel, Spain.
- 13 Servicio de Aparato Digestivo, Hospital General Universitario Doctor Balmis de Alicante, Spain.
- 14 Servicio de Aparato Digestivo, Hospital Clínico Universitario de Santiago de Compostela, Spain.
- 15 Servicio de Aparato Digestivo, Hospital Royo Villanova de Zaragoza, Spain.
- 16 Servicio de Aparato Digestivo, Hospital Universitario de Navarra, Spain.
- 17 Servicio de Aparato Digestivo, Hospital Universitario de Galdakao, Spain.
- 18 Servicio de Aparato Digestivo, Hospital San Jorge de Huesca, Spain.
- 19 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain; Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Spain; Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Spain.
- 20 Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet de Zaragoza, Spain.
- 21 Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Spain; Servicio de Aparato Digestivo, Hospital Clínico Lozano Blesa de Zaragoza, Spain.
Abstract
Objective:
the recommendations of the Spanish Ministry of Health on vaccination in risk groups include mesalazine among the treatments with a possible negative effect on its effectiveness. However, this is not the recommendation of most experts. Our objective was to evaluate the effect of mesalazine on the humoral response to the SARS-CoV-2 vaccine in patients with inflammatory bowel disease (IBD).
Methods:
VACOVEII is a Spanish, prospective, multicenter study promoted by GETECCU, which evaluates the effectiveness of the SARS-CoV-2 vaccine in patients with IBD. This study includes IBD patients who have recieved the full vaccination schedule and without previous COVID-19 infection. Seroconversion was set at 260 BAU/mL (centralized determination) and was assessed 6 months after full vaccination. In this subanalysis of the study, we compare the effectivenes of the vaccine between patients treated with mesalazine and patients without treatment.
Results:
A total of 124 patients without immunosuppressive therapy were included, of which 32 did not receive any treatment and 92 received only mesalazine. Six months after full vaccination, no significant differences are observed in the mean concentrations of IgG anti-S between both groups. In the multivariate analysis, antibody titers were independently associated with the use of mRNA vaccines and with SARS-CoV-2 infection.
Conclusion:
Mesalazine does not have a negative effect on the response to SARS-CoV-2 vaccines in IBD patients.
Keywords:
: SARS-CoV-2; Enfermedad Inflamatoria Intestinal; GETECCU; Inflammatory Bowel Disease; Mesalazina; Mesalazine; SARS-CoV-2; Vaccine; Vacuna.
Copyright © 2024. Publicado por Elsevier España, S.L.U.